This poster describes the characterization of NGS-based reference materials for fusion and somatic variant detection in myeloid cancers.
The large range of genetic aberrations and genes involved in myelogenous malignancies and clonal diseases of hematopoietic progenitor cells, which can lead to accumulation of immature blast cells in the bone marrow and peripheral blood, make next-generation sequencing (NGS) assays an important technology platform to determine these genetic changes.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences